Laurus Labs Ltd. News and Updates

Name: Latest research reports of Laurus Labs Ltd. authored by KRChoksey and published by - Trendlyne research reports.
Item: Laurus Labs Ltd.
Rating: 4
Author: KRChoksey

Keep track of all breaking news on Laurus Labs Ltd. from all sources in a single place.

Laurus Labs Ltd.

11 Apr 2025

605.85

7.37%

Laurus Labs surges 8%, stock records sharpest intraday gain since Jan 30

Business Standard

The pipeline is expected to be robust, and the company expects to do well in the human health and animal health CDMO divisions in Q4FY25E and in FY26E, according to analysts.

Laurus Labs Ltd. has gained 27.78% in the last 6 Months

Laurus Labs Ltd.

04 Apr 2025

605.85

7.37%

Laurus Labs to invest 5,000 crore in new manufacturing plant in Andhra Pradesh

Business Line

The State government will allot land for the proposed plant in Rambilli village, Anakapalli district

Laurus Labs Ltd. is trading above all available SMAs

Laurus Labs Ltd.

27 Jan 2025

605.85

7.37%

Laurus Labs shares down 15% on profit booking post Q3 earnings; Should you buy or sell?

livemint

Goldman Sachs has retained its Sell' rating on Laurus Labs, setting a price target of 475. The brokerage noted that although the management did not offer specific revenue guidance for FY2025.

Laurus Labs Ltd.'s price crossed above 100Day SMA today

Laurus Labs Shares Hit Two-Month Low Amid US Foreign Aid Pause, ARV Sales Concerns

NDTV Profit | 27 Jan 2025 1 more

Laurus Labs Ltd.

27 Jan 2025

605.85

7.37%

Late stage projects and high value API to drive growth

Accumulate: Laurus Labs Ltd.

Target

KRChoksey

Laurus Labs’ revenue beat our estimates significantly due to strong growth in Custom Synthesis segment and FDF segment. EBITDA beat our estimates due to better-than-expected gross profit and Adj. PAT beat our estimates due to strong operating performance.

Laurus Labs Ltd. has an average target of 587.75 from 4 brokers.

Laurus Labs Ltd.

27 Jan 2025

605.85

7.37%

Laurus Labs (SELL): Margin guidance shifted from 20% to closer to 20% for FY25E

Sell: Laurus Labs Ltd.

Target

BOB Capital Markets Ltd.

Revenue/EBITDA/PAT exceeded our estimates by 10.5%/46.6%/227%. EBITDA margin surpassed our estimate by 500bps

Laurus Labs Ltd. has gained 27.78% in the last 6 Months

Laurus Labs Ltd.

25 Jan 2025

605.85

7.37%

Laurus Labs Q3 Results 2025: Profit Soars 298.88% Year-on-Year

livemint

Laurus Labs Q3 Results 2025 on 25 Jan, 2025: Revenue increased by 18.42% YoY & profit increased by 298.88% YoY, profit at 92.3 crore and revenue at 1415.05 crore.

Laurus Labs Ltd.'s price crossed above 30Day SMA today

Laurus Labs Ltd.

25 Jan 2025

605.85

7.37%

Beat on earnings; green shoots visible

Buy: Laurus Labs Ltd.

Target

Motilal Oswal

Laurus Lab (LAURUS) significantly beat our earnings estimates in 3QFY25, led by a scale-up in the CDMO segment. Commercial supplies (including launch quantities) led to strong 89% YoY growth in CDMO sales for the quarter.